(RTTNews) -  Dyax Corp. (DYAX: News ) announced that an analysis demonstrating the ability of its lead product candidate DX-88 to resolve symptoms of acute hereditary angioedema attacks in all anatomic locations and to sustain effect would be presented this week at the American College of Allergy, Asthma and Immunology 2009 Annual Meeting.

The company noted that this evaluation, and two others to be presented, highlight efficacy and safety analyses from the integrated analysis of the two Phase 3 placebo-controlled trials, EDEMA3 and EDEMA4, of DX-88 for the treatment of acute attacks of HAE.
"Positive findings from the clinically stringent hurdle of complete or near complete resolution of an HAE attack provide encouraging evidence that treatment with DX-88 can potentially offer patients a quick and durable treatment for what is often a debilitating attack that can last for several days if untreated," commented Marc Riedl, MD, MS, Assistant Professor of Clinical Immunology and Allergy at the David Geffen School of Medicine at UCLA in Los Angeles.

Click here to receive FREE breaking news email alerts for Dyax Corp and others in your portfolio

by RTT Staff Writer

For comments and feedback: contact editorial@rttnews.com